Incyte will not proceed with Phase 3 Maestra-3 study in ovarian cancer
INCY•Incyte will not proceed with its Phase 3 Maestra-3 study of INCB123667 in ovarian cancer, citing portfolio prioritization. The company does not expect the decision to affect its financial guidance or long-term outlook and said it was not based on safety or efficacy.
1. Study decision
Incyte will not proceed with the Phase 3 Maestra-3 study of INCB123667 in ovarian cancer. The company said the decision was based on portfolio prioritization, not safety or efficacy, and does not expect it to affect financial guidance or its long-term outlook.
